drug
secnidazole
Marketedupdated 3mo agoby $EVFM Evofem Biosciences, Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying secnidazole
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 15, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Dec 11, 2041method-of-use (U-3302)US 12280037
- Sep 16, 2035formulationUS 11684607
- Sep 4, 2035formulationUS 10335390
- Sep 4, 2035formulationUS 10682338
- Sep 4, 2035formulationUS 10849884
- Sep 4, 2035formulationUS 10857133
- Sep 4, 2035formulationUS 11000507
- Sep 4, 2035formulationUS 11000508
- Sep 4, 2035formulationUS 11020377
- Sep 4, 2035formulationUS 11324721
- Sep 4, 2035formulationUS 11602522
FDA exclusivities (2)
- Sep 15, 2027GAINGAIN Antibiotic (5y)1.1y
- Sep 15, 2022NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that